About Bionxt
Bionxt is a company based in Vancouver (Canada) founded in 2018. Bionxt operates in a competitive market with competitors including Impel NeuroPharma, Ensysce, Arecor, Oxular and Souzhou Ribo Life Science, among others.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bionxt Solutions Inc
-
Annual Revenue
$18.75 K (USD)-92.75as on Dec 31, 2024
-
Net Profit
-$3.69 M (USD)31.22as on Dec 31, 2024
-
EBITDA
-$3.11 M (USD)27.98as on Dec 31, 2024
-
Latest Funding Round
$1.74 M (USD), Post-IPO
Feb 28, 2025
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bionxt
Bionxt is a publicly listed company on the CSE with ticker symbol BNXT in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Bionxt
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $1.7M
-
First Round
First Round
(03 Feb 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Post-IPO - Bionxt | Valuation |
investors |
|
| Jan, 2025 | Amount | Post-IPO - Bionxt | Valuation |
investors |
|
| Jan, 2025 | Amount | Post-IPO - Bionxt | Valuation |
investors |
|
Investments & Acquisitions by Bionxt
Financial Statements - Bionxt
Bionxt Comparisons
Competitors of Bionxt
Bionxt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, Ensysce, Arecor, Oxular and Souzhou Ribo Life Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| domain | founded_year | HQ Location |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| domain | founded_year | HQ Location |
Drug delivery platforms and therapeutics for ophthalmology are developed.
|
|
| domain | founded_year | HQ Location |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| domain | founded_year | HQ Location |
Erythrocyte encapsulation systems for drug delivery are developed.
|
Frequently Asked Questions about Bionxt
Bionxt was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Bionxt is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Hugh Rogers is the current CEO of Bionxt.
Annual revenue of Bionxt is $18.75K as on Dec 31, 2024.
Bionxt was founded in 2018 in Vancouver, Canada, within the biotechnology sector. Precision transdermal and oral dissolvable drug delivery formulations are developed, alongside rapid screening tests for infectious diseases and oral health. Clinical evaluations of active pharmaceutical ingredients for neurological applications are conducted. Operations center on improving drug accessibility, with Vektor provided as a formulation for efficient delivery of approved neurological medications.
Bionxt's top competitors include Oxular, PharmaJet and Impel NeuroPharma.
Yes, Bionxt is publicly traded on CSE under the ticker symbol BNXT.
The ticker symbol of Bionxt is BNXT on CSE.